杂志简称：j dermatol sci
中文译名：《皮肤科学杂志》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：2.40%
投稿方向：医学、dermatology 皮肤病学
SCI/E期刊基本信息
出版周期：月刊 地区：爱尔兰
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN0923-1811；EISSN1873-569X
杂志语言：英语
出版国家：爱尔兰
杂志官网 联系方式
出版地址：ELSEVIER IRELAND LTD,ELSEVIER HOUSE,BROOKVALE PLAZA,EAST PARK SHANNON,CO,CLARE,IRELAND,00000
杂志邮箱：
投稿网址：https://mc.manuscriptcentral.com/jdermscience
杂志官方网址：https://www.journals.elsevier.com/journal-of-dermatological-science
出版商网址：http://www.elsevier.nl
杂志投稿要求
投稿须知【杂志社官方网站信息】
Journal of Dermatological Science
Guide for Authors
JDS is committed to publishing peer-reviewed dermatological research and reviews. In addition to basic skin research, clinical research is within the scope of JDS when it is informative and well-performed. For example, JDS accepts submission of extensive clinical trials and retrospective clinical studies. However, studies on simple clinical use of undefined or as yet uncharacterized material are out of the scope of our journal. Original articles (research papers), letters to the Editor and review articles are welcomed. All manuscripts must be typed in English and must not be in submission or have been or be published in any other journal. The entire manuscript text should be typed double spaced, including the abstract, footnotes, references, legends and tables, with 3-cm margins. Any changes should not be included in the manuscript file (as tracked changes).
Authors must submit the relevant submission checklist with their manuscript:
•Checklist for Letters to the Editor
•Checklist for Original Articles (Research Papers)
• Checklist for Review Articles
Adobe Reader, click here http://get.adobe.com/reader/.
Type of Contribution
Original Articles (referred to as Research Papers)
Research papers should not exceed 3500 words, 6 figures including tables and contain no more than 50 references. A single figure or table can be made but should contain no more than 8 separate panels labelled from (a) to (h). Trade names must have an initial capital; the trivial name for a compound may be used if the formal, chemical name (as established by international convention) is given after the first use.
Basic and clinical scientific studies being submitted as a research paper should be organized as follows:
•Title Page (including the name of the corresponding author and their e-mail address)
•Structured abstract (maximum of 250 words and should be divided into the following sections: Background, Objective, Methods, Results, and Conclusion)
•Introduction
•Materials and Methods
•Results
•Discussion
•Acknowledgements
•References(Maximum of 50)
•Legends
•Tables and Figures.
Letters to the Editor
These will report original data or may discuss published articles. With the following exceptions, submission requirements for Letters to the Editor are the same as for regular manuscripts. Letters must be less than 1000 words in length, and cannot include more than 10 references and two figures (including tables). A single Figure or Table can be made but should contain no more than 8 separate panels labeled from (a) to (h). One panel may be composed of multiple figures with annotation around individual panels to make viewing easier. An abstract and subheadings should not be included in Letters to the editor.Comments may be solicited from authors if the letter refers to a particular article in the journal. Letters that report original data will be reviewed. All letters to the Editor are subject to editing and possible abridgement. Letters to the Editor will be included in the Medline database.
Review Articles
A specific field is reviewed through classical and up-dated literature. Review articles should not exceed 3500 words from introduction to conclusion, 3 figures (including tables)and contain no more than 50 references, except in exceptional circumstances. A single Figure or Table can be made but should contain no more than 8 separate panels labelled from (a) to (h). An abstract is required. Include in the review manuscript a short (maximum 100 words) biography of the first author, along with a passport-type photograph.
Contact Details for Submission
For inquiries about manuscripts please contact:
JDS Editorial office
Editor-in-Chief, Riichiro Abe
Department of Dermatology
Niigata University Graduate School of Medical and Dental Sciences
1-757 Asahimachi-dori, Chuo-ku, Niigata
951-8510, Japan
E-mail: jds@med.niigata-u.ac.jp
Ethics in publishing
Please see our information on Ethics in publishing.
Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also https://www.elsevier.com/conflictsofinterest. All authors must sign either the JDS Conflict of Interest Disclosure, which can be downloaded from JDS Conflicts.pdf or a statement declaring that the authors do not have any relevant conflicts of interest, which can be downloaded from JDS No Author Conflicts.pdf.
Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder. All authors must sign the JDS Author Declaration Form, which can be downloaded from: JDS Author declaration form.pdf.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Author comments to the Editor
Authors should enter their comments to the Editor on the ScholarOne website, including the following information: 1) The manuscript has not been submitted for publication elsewhere. 2) All authors have significantly contributed to the manuscript and all agree with its contents. 3) Authors do not have any relevant financial interests in the findings from this manuscript.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.
Requirements for clinical research trials
Human subject studies must have been approved by the authors' Institutional Review Board (IRB) or its equivalent. Authors will be asked to upload their IRB approval during the article submission process.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
Open access
Please visit our Open Access page for more information.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.
Microarray and RNA Sequencing Data
High throughput data (microarray and RNA sequencing data) should be deposited to the Gene Expression Omnibus (GEO) database at http://www.ncbi.nlm.nih.gov/geo/. Upon submission of manuscript, authors should supply their GEO accession numbers within the text of their manuscript (e.g., "GEO ID: GSE27196"). Upon publication, the ScienceDirect version of the article will automatically link to the relevant data.
Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.
Submit your article
Please submit your article via https://mc.manuscriptcentral.com/jdermscience.
Referees
Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.